Nanobiotix receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Nanobiotix (NANOB)
Nanobiotix stock price live, this page displays EPA NANOB stock exchange data. View the NANOB premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Nanobiotix real time stock price chart below.
What Is the Nanobiotix Stock Price Today?
The Nanobiotix stock price today is 35.56.
What Is the Stock Symbol for Nanobiotix?
The stock symbol for Nanobiotix is "NANOB."
What Stock Exchange Does Nanobiotix Trade On?
Nanobiotix is listed and trades on the Paris stock exchange.
Is Nanobiotix a Good Stock to Buy?
Determining whether Nanobiotix—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the NANOB quote. (ISIN: FR0011341205)
What Is the Nanobiotix Stock Price Today?
The Nanobiotix stock price today is 35.56.
What Is the Stock Symbol for Nanobiotix?
The stock symbol for Nanobiotix is "NANOB."
What Stock Exchange Does Nanobiotix Trade On?
Nanobiotix is listed and trades on the Paris stock exchange.
Is Nanobiotix a Good Stock to Buy?
Determining whether Nanobiotix—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the NANOB quote. (ISIN: FR0011341205)
35.56
+1.46(+4.28%)
Closed·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
33.96
37.16
52 wk Range
4.15
47.66
NANOB is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
33.9637.16
52 wk Range
4.1547.66
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
NANOB Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Analysts Sentiment
Strong Buy
Price Target
47.80
Upside
+34.42%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
High return over the last year
- Nanobiotix receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Nanobiotix receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Nanobiotix receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- Nanobiotix receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Nanobiotix receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Nanobiotix receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Nanobiotix receives Investment Bank Analyst Rating Update
- Investing.com
Pro
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy
Analyst Ratings
4 Buy
1 Hold
0 Sell
Ratings:
5 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 47.80
(+34.42% Upside)
Earnings
Latest Release
May 29, 2026
EPS / Forecast
-- / --
Revenue / Forecast
-- / --
Compare NANOB to Peers and Sector
Metrics to compare | NANOB | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipNANOBPeersSector | |
|---|---|---|---|---|
P/E Ratio | −77.6x | −2.8x | −0.4x | |
PEG Ratio | −1.11 | −0.02 | 0.00 | |
Price/Book | −22.0x | 0.8x | 2.6x | |
Price / LTM Sales | 57.0x | 16.8x | 3.0x | |
Upside (Analyst Target) | 32.0% | 255.5% | 51.9% | |
Fair Value Upside | Unlock | 8.8% | 9.1% | Unlock |
Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck, liver, prostate, pancreatic, esophageal, rectal, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is based in Paris, France.
Ownership
Ownership Overview
Top Holders
FAQ
What Is the Nanobiotix (NANOB) Stock Price Today?
The Nanobiotix stock price today is 35,56 EUR.
What Stock Exchange Does Nanobiotix Trade On?
Nanobiotix is listed and trades on the Paris Stock Exchange.
What Is the Stock Symbol for Nanobiotix?
The stock symbol for Nanobiotix is "NANOB."
What Is the Nanobiotix Market Cap?
As of today, Nanobiotix market cap is 1,79B EUR.
What Is Nanobiotix's Earnings Per Share (TTM)?
The Nanobiotix EPS (TTM) is -0,50.
When Is the Next Nanobiotix Earnings Date?
Nanobiotix will release its next earnings report on Sep 30, 2026.
From a Technical Analysis Perspective, Is NANOB a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has Nanobiotix Stock Split?
Nanobiotix has split 1 times.
How Many Employees Does Nanobiotix Have?
Nanobiotix has 100 employees.
What is the current trading status of Nanobiotix (NANOB)?
As of Jul 10, 2026, Nanobiotix (NANOB) is trading at a price of 35,56 EUR, with a previous close of 34,10 EUR. The stock has fluctuated within a day range of 33,96 EUR to 37,16 EUR, while its 52-week range spans from 4,15 EUR to 47,66 EUR.
What Is Nanobiotix (NANOB) Price Target According to Analysts?
The average 12-month price target for Nanobiotix is 47,80 EUR, with a high estimate of 60 EUR and a low estimate of 34 EUR. 4 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +34,42% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.